PLK1 and cancer: TKM-080301, 0.3-0.75 mg/kg 3+3 dose-escalation study once a week, and ATU027, 0.253 mg/kg once or twice a week, from Arbutus Biophama Corp. which target polo-like kinase 1 (PLK1) and protein kinase N3 (PKN3) inhibits cancer cell proliferation and vascularization respectively 272, 273.